The two faces of reactive oxygen species in cancer

Research output: Contribution to journalArticlepeer-review

387 Scopus citations


Reactive oxygen species (ROS), now appreciated for their cellular signaling capabilities, have a dual role in cancer. On the one hand, ROS can promote protumorigenic signaling, facilitating cancer cell proliferation, survival, and adaptation to hypoxia. On the other hand, ROS can promote antitumorigenic signaling and trigger oxidative stress-induced cancer cell death. To hyperactivate the cell signaling pathways necessary for cellular transformation and tumorigenesis, cancer cells increase their rate of ROS production compared with normal cells. Concomitantly, in order to maintain ROS homeostasis and evade cell death, cancer cells increase their antioxidant capacity. Compared with normal cells, this altered redox environment of cancer cells may increase their susceptibility to ROS-manipulation therapies. In this review, we discuss the two faces of ROS in cancer, the potential mechanisms underlying ROS signaling, and the opposing cancer therapeutic approaches to targeting ROS.

Original languageEnglish (US)
Pages (from-to)79-98
Number of pages20
JournalAnnual Review of Cancer Biology
StatePublished - 2017

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology


Dive into the research topics of 'The two faces of reactive oxygen species in cancer'. Together they form a unique fingerprint.

Cite this